Glaukos Corp insider trading
Every open-market purchase and sale by Glaukos Corp's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Glaukos Corp’s insiders pay?
From November 12, 2015 to September 1, 2026, 15 insiders reported 5 open-market purchases and 42 sales not made under a pre-set plan in Glaukos Corp. Twelve months after each purchase was reported, the shares were +66.4% against the S&P 500 on average (median +30.9%), over 5 purchases with a full year of prices; 100% beat the index. After sales, the shares moved +3.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 13, 2015 into $52,265 by November 2, 2026, +16.3% a year. It held shares 21% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $16,147 (+4.5% a year), and held throughout $44,677 (+14.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Kliman Gilbert H | Director | 0 | — | — | 12 | −3.8% (8) | August 20, 2026 |
| Silverstein Jonathan | Director | 0 | — | — | 7 | +5.3% (7) | March 6, 2018 |
| Gilliam Joseph E | PRESIDENT & COO | 1 | +120.1% (1) | 100% | 3 | — | August 13, 2026 |
| Link William J Phd | Director | 0 | — | — | 4 | −22.5% (4) | December 3, 2020 |
| Weisner Aimee S | Director | 2 | +83.3% (2) | 100% | 2 | −46.1% (1) | February 23, 2026 |
| Orbimed Capital Gp III LLC | Director | 0 | — | — | 3 | −20.3% (3) | August 17, 2017 |
| Foley Mark J | Director | 0 | — | — | 2 | +0.5% (2) | February 28, 2025 |
| Isaly Samuel D | Director | 0 | — | — | 2 | −3.4% (2) | September 5, 2017 |
| Orbimed Advisors LLC | Director | 0 | — | — | 2 | +52.2% (2) | March 6, 2018 |
| Wen Leana | Director | 0 | — | — | 2 | — | August 3, 2026 |
| Burns Thomas William | Chief Executive Officer | 1 | +22.6% (1) | 100% | 0 | — | January 4, 2016 |
| Harrison Richard L | Treasurer, CFO & Secretary | 1 | +22.6% (1) | 100% | 0 | — | January 4, 2016 |
| Montreux Equity Management IV, LLC | 10% owner | 0 | — | — | 1 | +151.6% (1) | February 26, 2016 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER | 0 | — | — | 1 | — | September 1, 2026 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | 0 | — | — | 1 | +52.3% (1) | December 18, 2023 |
When several insiders traded Glaukos Corp
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Glaukos Corp in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +101.0% against the index. After 3 selling crowds, −4.6%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 29, 2026 | 3 selling | +72.1% | not yet | not yet |
| September 29, 2017 | 3 selling | −29.0% | −9.3% | +70.4% |
| March 31, 2017 | 3 selling | −22.2% | −43.3% | −51.3% |
| August 31, 2016 | 5 selling | +2.7% | +38.9% | +10.3% |
| January 29, 2016 | 3 buying | +8.4% | +101.0% | +113.2% |